Inside a new manufacturing facility in Roanoke, something ordinarily found in a refrigerator is being prepared for a far more ambitious purpose.

Roanoke, VA

Author: Roanoke Rambler Staff, Tina Charisma

Published: 9:47 AM EST September 2, 2026

Edited: 9:57 AM EST September 2, 2026

Tiny Cargo Company is extracting microscopic particles from cow's milk that it hopes can carry fragile medicines safely through the human body.

The particles are not themselves a medicine. And the company's lead experimental treatment is still a long way from reaching patients.

But its journey has already passed through several places that do not usually exist so close together: a university research laboratory, a biotechnology startup, a specialized incubator and a manufacturing facility.

All of them are in Roanoke.

Before a patient can swallow a new medicine, somebody has to discover it, finance it, test it, manufacture it and navigate years of federal regulation. Failure can come at almost any point—and promising companies often have to leave smaller regions to find the facilities, expertise and investment they need.

Tiny Cargo has not had to leave yet.

Born from research conducted at the Fralin Biomedical Research Institute at Virginia Tech, the company opened a specialized manufacturing facility in Roanoke in February. Its drug-loading and quality-control laboratory now operates from RoVa Labs, the region's new biotechnology incubator, a few miles away.

How much further Tiny Cargo can travel here may reveal whether Roanoke is building more than a collection of biomedical institutions.

Could a medicine one day make the entire journey from laboratory to patient without leaving the region?

From milk to medicine

Tiny Cargo began inside the laboratory of Virginia Tech researcher Rob Gourdie at the Fralin Biomedical Research Institute.

The research centered on exosomes, microscopic particles naturally used by cells to transport biological material.

Milk contains them.

Because milk exosomes have evolved to survive being consumed, researchers saw a potentially useful characteristic: They might be able to carry fragile therapeutic compounds through the digestive system without those compounds being destroyed before reaching their destination.

"The starting point was a simple idea: Milk exosomes are nature's own delivery system, evolved to be ingested orally and then carry fragile cargo safely around the body and to where they are needed," Tiny Cargo CEO Alan Gourdie told The Roanoke Rambler in written responses.

"The problem we work on is an old and stubborn one—getting a delicate medicine where it needs to go, intact."

Spencer Marsh was involved in developing the exosome technology during its early stages in Rob Gourdie's laboratory. He is now Tiny Cargo's chief scientific officer.

Eventually, the research moved beyond the university.

Tiny Cargo was created as a spinout from FBRI, beginning the complicated process of transforming academic research into a commercial biotechnology company.

That transition is one of the first places promising discoveries can stall.

A scientific result does not automatically become a product. Researchers need intellectual-property protection, financing, business expertise, laboratory facilities and a pathway through federal regulation.

Alan Gourdie credited the company's relationships with FBRI, Virginia Tech and Virginia Tech Intellectual Properties with helping it make that transition.

"The science was born here, so in one sense Roanoke chose us," he said.

Building an experimental drug

Today, Tiny Cargo is attempting to turn that research into an actual treatment.

Its lead experimental drug, XOlacta, combines milk exosomes with the company's proprietary wound-healing peptide, aCT11.

Tiny Cargo is investigating the treatment for two potential applications. One is as a radioprotectant intended to reduce damage to healthy tissue when cancer patients receive radiation therapy. The other is as a cardioprotectant intended to limit lasting damage to heart muscle following a heart attack.

The company says its preclinical research has advanced in both areas with support from federal grant funding.

But "preclinical" is an important distinction.

XOlacta is not an FDA-approved medicine. It has not yet completed the sequence of human clinical trials required before a new drug can potentially reach patients.

The regulatory distinction is particularly important in the emerging exosome field. The FDA says there are currently no FDA-approved exosome products and that products intended to treat diseases or conditions in humans generally require federal review and approval. Researchers and regulators have also identified the development of consistent quality-control standards as a challenge for manufacturing extracellular-vesicle products.

That distance between a promising scientific finding and an approved treatment is central to understanding biotechnology.

Researchers must establish safety and effectiveness, develop reliable manufacturing methods and satisfy federal requirements before a treatment can become widely available. Even a drug that enters clinical trials may never receive approval.

Tiny Cargo therefore represents both the promise and the uncertainty of the process Roanoke is trying to support.

The factory step

One of the company's most significant transitions happened this year.

In February, Tiny Cargo officially opened a manufacturing plant in Roanoke that includes more than 2,000 square feet of cleanroom space for producing milk-derived exosomes at industrial scale. The facility represented a roughly $1.5 million buildout, according to the Virginia Innovation Partnership Corporation, the state's innovation-funding arm.

The company says it has completed its first industrial production runs and is working toward the regulatory requirements necessary for manufacturing at commercial and licensing scale.

That matters for more than Tiny Cargo.

Manufacturing is one of the points at which a region trying to build a biotechnology sector can lose companies.

A startup may be able to conduct early research in a university laboratory. As biotechnology companies grow, however, they require specialized facilities, quality-control systems, equipment and employees capable of operating within strict regulatory requirements.

If that infrastructure does not exist locally, companies may have to find it elsewhere.

Alan Gourdie said Roanoke gave Tiny Cargo an alternative. The company could build a current Good Manufacturing Practice, or cGMP, facility here with access to space and workers at a cost that would have been difficult to match in a larger biotechnology cluster.

"You can do serious, regulated manufacturing here, not just early research," he said.

That proposition is important to Roanoke's larger ambitions. A region capable of producing scientific discoveries but unable to manufacture the resulting products may capture only part of their economic value.

Tiny Cargo says it intends to do both here.

"We are a manufacturer as well as a research company, and that matters for a regional economy," Gourdie said.

Filling the space between discovery and company

There is now another piece of Roanoke's biotechnology pipeline—and its timing tells its own story.

RoVa Labs, a roughly 40,000-square-foot, $26 million biotechnology incubator near FBRI, the Virginia Tech Carilion School of Medicine and Carilion Roanoke Memorial Hospital, opened in May, about two and a half months after Tiny Cargo's manufacturing plant.

The state-backed facility was created after an economic-development study identified local demand for space where biomedical research could be commercialized. It is intended to occupy the space between research and industry by providing legal, accounting, human-resources and grant-writing support alongside wet-laboratory space for companies navigating regulatory requirements and early business formation.

In other words, Tiny Cargo had already moved beyond the earliest stage of the pipeline before the region finished building an incubator designed to support it.

Tiny Cargo became RoVa Labs' first tenant, establishing its drug-loading and quality-control laboratory there. Its manufacturing plant operates separately, a few miles away.

That means different stages of one biotechnology company's development—academic research, commercialization, laboratory development and manufacturing—have occurred within the same region.

That is precisely the pipeline Roanoke is attempting to build.

But the next stages become harder.

Can Roanoke complete the journey?

Before XOlacta could become a medicine available to patients, Tiny Cargo would have to continue its preclinical development and satisfy federal requirements to begin testing the drug in humans.

Clinical trials would then have to determine whether the treatment is safe and effective. Successful trials would still not guarantee federal approval.

If the drug ultimately reached the market, the company would need sufficient manufacturing capacity, financing, regulatory expertise and workers to produce it reliably on a much larger scale.

Each stage requires different infrastructure. That may be a more useful way of measuring Roanoke's claim to an emerging biotechnology sector than simply counting research institutions, laboratories or companies.

The real question is how far a company can travel without leaving.

Roanoke clearly possesses some of the early pieces: biomedical researchers, university intellectual property, startup support, specialized laboratory space and an established health system. Tiny Cargo demonstrates that specialized manufacturing can happen here as well.

That proposition is being tested during a particularly challenging period for early-stage biotechnology companies.

Although biopharma investment increased nationally during the first half of 2026, industry analyses indicate that investors are writing fewer, larger checks and concentrating capital among companies that can show clinical data or commercial momentum. An analysis by BioPharma Dive found that about two-thirds of the venture rounds it tracked during the first half of the year went to companies that already had a drug prospect in human testing.

For a preclinical company such as Tiny Cargo, the challenge is not simply producing promising science. It is securing enough capital and expertise to survive the expensive journey toward human trials.

What remains unproven is whether the region has the later-stage capital, experienced biotechnology executives, regulatory specialists, clinical-research capacity and workforce needed to support companies as their needs become larger and more complex.

A medical school and hospital system do not automatically guarantee that every stage of a drug's clinical development can occur locally. Clinical trials require specialized investigators, patient-recruitment systems, regulatory oversight, financing and infrastructure specific to the treatment being studied.

If a Roanoke discovery eventually requires its company to relocate to Boston, San Francisco, Research Triangle Park or another established life-sciences cluster to complete development, the science may have originated here while much of its economic value accumulates somewhere else.

If companies can remain, Roanoke could capture something more enduring.

RoVa Labs, which by midsummer had only one announced tenant two months after opening, represents an early test of whether the region can generate enough biotechnology businesses to fill the infrastructure it has built.

From lab to patient

Tiny Cargo is also pursuing uses for its technology beyond XOlacta.

Its drug-loading platform is designed to use milk exosomes to carry other medicines, with the longer-term possibility that some drugs currently delivered by injection could instead be taken orally.

Alan Gourdie said the company has signed several collaborative agreements with major pharmaceutical companies involving the platform. Tiny Cargo has also launched XO-Cargo, a line applying its exosome technology to cosmetic ingredients.

The cosmetics business could provide a more immediate commercial use for the technology while the company continues the much longer and less certain process of developing a pharmaceutical product.

Over the next five years, Gourdie said success would mean moving XOlacta toward clinical development, expanding pharmaceutical partnerships, increasing international use of the company's cosmetic ingredients and expanding its manufacturing operation in Roanoke.

Tiny Cargo's ambition, he said, is to become a "growing, self-sustaining company rooted in Roanoke."

Roanoke has demonstrated that biomedical research can begin here, that a company can emerge from it and that specialized manufacturing can follow.

What it has not demonstrated is whether a locally discovered treatment can complete clinical development without the company—or much of its economic value—moving elsewhere.

The real test of Roanoke's biotechnology ambitions will not be how many laboratories it builds, but how far the discoveries inside them can travel without leaving the region.